Brodalumab: 5-Year US Pharmacovigilance Report.
Mark G LebwohlJohn Y KooApril W ArmstrongBruce E StroberGeorge M MartinNicole N RawnsleyEarl L GoehringAbby A JacobsonPublished in: Dermatology and therapy (2024)
Five-year pharmacovigilance data are consistent with the established safety profile reported in long-term clinical trials and previous pharmacovigilance reports, with no new safety signals.